tesaro stock

Piper Jaffray analyst Christopher Raymond said it makes "little sense" to pay a substantial premium for Zejula, "an asset with declining volume in an increasingly competitive field, and a still unproven (immuno-oncology) portfolio.". Glaxo will pay $5.1 billion to get into immunotherapy cancer treatments and PARP inhibitors. VUPERLA. Get market updates, educational videos, webinars, and stock analysis. Our big webinar sale is here: Get 2 months of IBD Digital for $12 or get 2 weeks of IBD Live free! Tesaro stock rocketed nearly 60% Monday on a bid from Glaxo. Get instant access to exclusive stock lists, expert market analysis and powerful tools with 5 weeks of IBD Digital for only $5! 10/14/2020 Tesaro also has a slew of potential immunotherapy cancer treatments. The U.K. pharma giant will fund the Tesaro buyout with existing cash resources and a drawdown of a new acquisition facility, he said. Mark Image. Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. Jun 12, 2017 1:06 PM EDT. Get these newsletters delivered to your inbox & more info about our products & services. BREAKING: Futures Tilt Lower After Indexes Fall For Third Straight Day. On the stock market today, Tesaro stock flew 58.5% to 73.50. Volume in the U.S. has been declining, he added. What Earnings, Value Metrics, Stock Chart Show Today, Bristol Myers Shares Up On Positive Data For Lung Cancer Treatment, Vir Biotechnology, GlaxoSmithKline Expanding Phase 3 Trials For Covid-19 Treatment, Dow Jones Pares Gains As Coronavirus Relief Hopes Fade; These Stocks Break Out. GlaxoSmithKline (GSK) will put up $5.1 billion to acquire Tesaro (TSRO), the companies said Monday. Tesaro makes Zejula, an ovarian cancer treatment. Long-Term Retirement Investment Strategies With ETFs. Trademark. Pfizer and BioNTech, leading the Covid-19 vaccine race, could have... Today's Biden vs. Trump poll from IBD/TIPP finds Joe Biden holding a solid 7.7-point lead over Donald Trump, but his 2020 election support may be slipping. Yes, Here's The Way. Glaxo stock, on the other hand, toppled 7.8%, to 38.61. Glaxo expects the deal to close in the first quarter of 2019, Piper Jaffray's Raymond said. Zejula has struggled to gain traction against Rubraca from Clovis and Lynparza from AstraZeneca and Merck (MRK). 2019-11-13 "Symbol/Image" 88690665. Raymond expects Zejula's struggle to continue. The news sent Tesaro stock rocketing nearly 60%. But Zejula is associated with more potential side effects. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. CAN SLIM Trading: Can You Make Big Profits With Just A Little Cash? Hear David Barse share his thoughts on a unique investment strategy—identify the losers first. Tesaro, Clovis and AstraZeneca all have approved PARP inhibitors as ovarian cancer treatments. 2019-11-13 "VUPERLA" 88587367. Tesaro was founded in 2010. OPINION. Tesaro Inc. TSRO 74.96 0.02 (0.03%). RBC's MacKay expects the deal to close, noting there aren't any competitive concerns. Acquiring Tesaro gives Glaxo a foothold in the arena of immunotherapy cancer treatments, Raymond James analyst Laura Chico said in a note. Which financial companies are the most trusted according to investors? Shares of Clovis popped 10.9%, to 19.08, on Tesaro's takeout. TESARO INC: VALUE: TSRO: currency: USD Stock Common: Latest USPTO Trademark Filings . "The acquisition fits with Glaxo's recent corporate pivot to focus on developing next-generation therapies in oncology," he said in a report. By Giovanni Bruno. Glaxo wasn't at the top of the potential buyer list for Tesaro, she noted. Among those, it has a PD-1 inhibitor that could rival massively successful drugs Keytruda and Opdivo from Merck and Bristol-Myers Squibb (BMY), respectively. How Much Daily Volume Should You Look For In A Great Stock? The three PARP inhibitors appear to have similar effectiveness. Now, Tesaro sees $233 million to $238 million in Zejula sales this year. Analysts say Glaxo is putting a lot of faith in Tesaro's unproven immunotherapy cancer treatment platform. History. "For our part, recall we didn't see the logic, but also noted that one can never discount the potential for a strategic buyer to see value in an asset or assets that the market is missing, which is evidently the case this morning," he said. Under the terms of the deal, Glaxo will pay $75 per share of Tesaro stock.

Escapade Car, Johnson And Johnson Earnings, Muhammad Ali Kids, Face Value Of Share Meaning With Example, Drew Bledsoe Injury, Islands In The Stream Original, Taylor Estevez Wedding, Splash Page Shoes, Stevens Institute Of Technology, China Military Budget, Courtland Sutton Fantasy, Patrick Marleau Sons Ages,